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ABSTRACT
Background Data are conﬂicting regarding the
possible effects of statins in patients with idiopathic
pulmonary ﬁbrosis (IPF). This post hoc analysis assessed
the effects of statin therapy on disease-related outcomes
in IPF.
Methods Patients randomised to placebo (n=624) in
three controlled trials of pirfenidone in IPF (CAPACITY
004 and 006, ASCEND) were categorised by baseline
statin use. Outcomes assessed during the 1-year
follow-up included disease progression, mortality,
hospitalisation and composite outcomes of death or
≥10% absolute decline in FVC and death or ≥50 m
decline in 6-minute walk distance (6MWD).
Results At baseline, 276 (44%) patients were statin
users versus 348 (56%) non-users. Baseline
characteristics were similar between groups, except statin
users were older and had higher prevalence of
cardiovascular disease and risk factors. In multivariate
analyses adjusting for differences in baseline
characteristics, statin users had lower risks of death or
6MWD decline (HR 0.69; 95% CI 0.48 to 0.99,
p=0.0465), all-cause hospitalisation (HR 0.58; 95% CI
0.35 to 0.94, p=0.0289), respiratory-related
hospitalisation (HR 0.44; 95% CI 0.25 to 0.80,
p=0.0063) and IPF-related mortality (HR 0.36; 95% CI
0.14 to 0.95, p=0.0393) versus non-users. Non-
signiﬁcant treatment effects favouring statin use were
observed for disease progression (HR 0.75; 95% CI 0.52
to 1.07, p=0.1135), all-cause mortality (HR 0.54;
95% CI 0.24 to 1.21, p=0.1369) and death or FVC
decline (HR 0.71; 95% CI 0.48 to 1.07, p=0.1032).
Conclusions This post hoc analysis supports the
hypothesis that statins may have a beneﬁcial effect on
clinical outcomes in IPF. Prospective clinical trials are
required to validate these observations.
Trial registration numbers NCT01366209,
NCT00287729 and NCT00287716.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a serious,
debilitating and progressive lung disease that pre-
sents with exertional dyspnoea and cough.1–3 IPF is
diagnosed more frequently among men than
women, during the seventh or eighth decade of life
and among current or ex-smokers.4 IPF is asso-
ciated with substantial healthcare requirements and
patients with IPF typically require frequent hospita-
lisations as a consequence of their disease.5
Furthermore, the prognosis for patients with IPF is
poor and survival rates are lower than those
reported for many common cancers.6 7 The 5-year
survival rate for patients from the time of diagnosis
is between 20% and 40%,8 with a median survival
of between 2 years and 5 years.2 7
Two antiﬁbrotic drugs are approved for the treat-
ment of IPF, pirfenidone9 10 and nintedanib.11
Both drugs have been shown to signiﬁcantly reduce
the decline in FVC compared with placebo among
patients with IPF.9–11 Pirfenidone has also been
shown to improve survival among patients with
IPF: a pooled analysis of data found a 48% reduc-
tion in mortality compared with placebo after
1 year of treatment with pirfenidone (p=0.01).9
Cardiovascular (CV) comorbidities are common
in IPF12 and medications are often required to treat
patients with CV risk factors. This includes the
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
inhibitor or ‘statin’ class of drugs, which are widely
used for their cholesterol-lowering effects and asso-
ciated reduction in the risk for CV morbidity.13 14
The potential for additional beneﬁts from statin
therapy has been investigated previously. For
example, statins have been shown to attenuate the
decline in pulmonary function associated with
normal ageing, with the magnitude of the protect-
ive effect apparently modiﬁed by smoking status.15
Furthermore, the effect of statins on disease-related
outcomes in patients with COPD has also been
Key messages
What is the key question?
▸ Do statins have an effect on disease-related
outcomes in patients with idiopathic pulmonary
ﬁbrosis (IPF)?
What is the bottom line?
▸ In a large and well deﬁned cohort of patients
with IPF, statins were associated with
reductions in IPF-related mortality,
hospitalisation and disease progression
compared with patients who did not receive
statins.
Why read on?
▸ Statins are frequently prescribed for
concomitant cardiovascular disease and risk
factors in patients with IPF, and have previously
been linked with both detrimental and
beneﬁcial actions on IPF progression.
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investigated.16 However, the relationship between statins and
the development of interstitial lung disease (ILD) is controver-
sial. Case reports and, most recently, a regression analysis of
current and former smokers included in the COPDGene study
suggest that statin use may be associated with the presence of
interstitial lung abnormalities, at least among patients who are
current or ex-smokers.17 18
In contrast, a recent analysis of a health administrative data-
base that included 6665 individuals with possible or probable
ILD and 26 660 matched control subjects, did not reveal an
association between statin use and the incidence of ILD.19
Conﬂicting data have also emerged with regard to the effect of
statins in patients with established lung disease such as IPF.
Animal studies have shown that statins prevent the development
of pulmonary ﬁbrosis, although they do not appear to attenuate
established pulmonary ﬁbrosis.20 In a small retrospective ana-
lysis of data from 35 patients with IPF, no association between
statin therapy and mortality was identiﬁed.21 However, a more
recent analysis of data from the national Danish Patients
Registry found that statin use was associated with reduced mor-
tality among patients with ILD, including those with IPF.22
To further investigate the potential effects of statins in
patients with IPF, a post hoc analysis was performed using data
from the placebo arms of the pirfenidone phase III programme.
The effect of statins on mortality and other clinically relevant
disease-related outcomes was investigated in this well deﬁned
population of patients with IPF.
MATERIALS AND METHODS
This was a post hoc analysis of data from the placebo arms of
three phase III, randomised, controlled, double-blind clinical
trials of pirfenidone in IPF: Study 016, Assessment of
Pirfenidone to Conﬁrm Efﬁcacy and Safety in Idiopathic
Pulmonary Fibrosis (ASCEND; NCT01366209);9 and Study
004 and Study 006, Clinical Studies Assessing Pirfenidone in
Idiopathic Pulmonary Fibrosis (CAPACITY; NCT00287729 and
NCT00287716, respectively).10 Patient enrolment took place
from July 2011 to January 2013, and from April 2006 to
November 2008 in the ASCEND and CAPACITY trials, respect-
ively. ASCEND and CAPACITY were conducted in accordance
with the International Conference on Harmonisation Guidelines
and the Declaration of Helsinki, as well as the relevant local
legal and regulatory requirements of the countries in which the
trials were conducted. Written informed consent was obtained
from all patients prior to any study procedure.
Patients
ASCEND and CAPACITY recruited patients aged between
40 years and 80 years who had a conﬁrmed diagnosis of IPF by
high-resolution CT (HRCT) alone or HRCT plus surgical lung
biopsy. Eligible patients had an FVC ≥50% (and ≤90% in the
ASCEND trial), per cent predicted carbon monoxide diffusing
capacity ≥35% (≥30% and ≤90% in the ASCEND trial) and a
6-minute walk distance (6MWD) ≥150 m with no evidence of
improvement in measures of IPF disease severity over the pre-
ceding year. Patients showing signiﬁcant clinical worsening of
IPF as judged by the investigator, or a difference in FVC >10%
between screening and day 1, were excluded. Other exclusion
criteria were clinically signiﬁcant concomitant disease including
a history of unstable or deteriorating cardiac disease within the
previous 6 months, and active infection or malignancy. Patients
with a history of COPD were excluded from ASCEND, but
were eligible for the CAPACITY studies if the condition had not
led to hospitalisation within 6 months prior to study entry.9 10
The use of concomitant medication, including statins, was ascer-
tained through open-ended questioning by study investigators.
Assessments
The outcomes evaluated were disease progression (deﬁned as
the ﬁrst occurrence of any of the following: ≥10% absolute
decline in per cent predicted FVC, a decline of at least 50 m in
6MWD (both required conﬁrmation at two consecutive assess-
ments at least 6 weeks apart) or death), all-cause mortality,
IPF-related mortality (the cause of death was assessed by
blinded clinical investigators in CAPACITY and a mortality
assessment committee in ASCEND), change from baseline in
FVC, change from baseline in 6MWD, all-cause hospitalisation
and respiratory-related hospitalisation (deﬁned as a hospitalisa-
tion in which the primary reason for admission was determined
to be respiratory related by the investigator). The composite
outcomes of all-cause mortality or a ≥10% absolute decline in
per cent predicted FVC and all-cause mortality or a ≥50 m
decline in 6MWD were prespeciﬁed outcomes in ASCEND.9 All
outcomes were evaluated over 1 year.
Statistical analysis
Demographic and clinical characteristics of the study population
categorised by statin use at baseline, and corresponding crude
(unadjusted) risks of binary study outcomes among statin users
and non-users, were compared. Statistical comparisons were
undertaken using an independent-samples t-test for continuous
variables and a χ2 test for categorical variables.
A shared frailty model (an extension of the Cox proportional
hazards model that adjusts for intracluster (ie, intratrial) correl-
ation) was employed to examine the relationship between statin
use and study outcomes without adjustment (bivariate model),
and with adjustment for age, sex, smoking status, lung function,
exercise tolerance, dyspnoea, medical history and CV risk
factors (multivariate model). Survival analyses were based on
the Kaplan-Meier estimator, and comparisons of statin users and
non-users were based on the log-rank test. Only observed data
were employed in analyses (ie, missing values were not
imputed). Individuals were censored at the time of loss to
follow-up, at the time of lung transplantation or at the end of
the 1-year follow-up period, whichever occurred ﬁrst. The pres-
ence of multicollinearity, hazards assumptions and treatment of
death as a competing risk (where appropriate) were evaluated
using published methods.23 24 SAS V.9.3 for Windows was used
to evaluate the proportionality assumption for statin use using a
time-dependent covariate (ie, interaction between statin and
time). Models not considering death as an outcome were esti-
mated, alternatively treating death as a competing risk rather
than censoring on death.
RESULTS
Patients
A total of 624 patients were included in this post hoc analysis
(ASCEND, n=277; CAPACITY, n=347), of whom 276 (44.2%)
were receiving statin therapy at baseline (simvastatin, 38.4%;
atorvastatin, 34.8%; pravastatin, 9.8%; rosuvastatin, 9.4%;
other, 7.6%). The mean (SD) duration of follow-up was 348.3
(58.8) days in patients who received statins and 342.7 (67.8)
days in those who did not. During the 1-year follow-up, one
statin user and four statin non-users received a lung transplant.
Statin users were older than non-users and a greater propor-
tion of statin users were male (table 1).
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Baseline lung function and exercise capacity were similar
between the two groups. However, those receiving statins had a
signiﬁcantly higher prevalence of CV disease at baseline. The
prevalence of the following CV risk factors was higher among
statin users than non-users: hypertension, smoking (current and
former), diabetes and hypercholesterolaemia (table 1).
Disease-related outcomes
Results from the crude analysis and bivariate frailty model are
presented in table 2.
In multivariate analyses, there was a non-signiﬁcant treatment
effect favouring statin use for the composite disease-progression
outcome (multivariate HR 0.75; 95% CI 0.52 to 1.07,
p=0.1135) (ﬁgure 1; table 3). Statin users had a signiﬁcantly
lower risk versus non-users for the composite outcome of all-
cause mortality or a decrease of ≥50 m in 6MWD (multivariate
HR 0.69; 95% CI 0.48 to 0.99, p=0.0465), all-cause hospital-
isation (multivariate HR 0.58; 95% CI 0.35 to 0.94,
p=0.0289), respiratory-related hospitalisation (multivariate HR
0.44; 95% CI 0.25 to 0.80, p=0.0063) and IPF-related mortal-
ity (multivariate HR 0.36; 95% CI 0.14 to 0.95, p=0.0393)
(table 3). There was no signiﬁcant difference between treatment
groups for ≥10% absolute decline in per cent predicted FVC
(multivariate HR 0.81; 95% CI 0.47 to 1.40, p=0.4533), the
composite outcome of all-cause mortality or a ≥10% decline in
per cent predicted FVC (multivariate HR 0.71; 95% CI 0.48
to 1.07, p=0.1032) (ﬁgure 2) and all-cause mortality (multivari-
ate HR 0.54; 95% CI 0.24 to 1.21, p=0.1369) (table 3).
DISCUSSION
The results of this post hoc analysis of data from patients with
IPF from the placebo arms of the CAPACITY and ASCEND
trials provide support for the hypothesis that statin therapy may
have a beneﬁcial effect on IPF-related outcomes. In particular,
statins were associated with reduced hospitalisation and
mortality.
Table 1 Summary of baseline demographics: baseline statin users
and non-users
Parameter
Statin users
(N=276)
Statin non-users
(N=348) p Value
Mean age, years (SD) 68.2 (7.0) 66.3 (7.8) 0.0014
Sex, n (%)
Male 225 (81.5) 240 (69.0) 0.0004
Mean % predicted FVC (SD) 72.5 (14.0) 71.6 (13.3) 0.4297
Mean % predicted DLco* (SD) 45.4 (10.3) 45.7 (11.7) 0.7329
Mean 6MWD*, m (SD) 407.4 (89.8) 415.3 (97.6) 0.3028
Mean UCSD-SOBQ score* (SD) 34.3 (22.1) 35.4 (21.2) 0.5325
Medical history, n (%)
Cardiovascular disease 127 (46.0) 53 (15.2) <0.0001
Chronic renal failure 13 (4.7) 7 (2.0) 0.0573
COPD 14 (5.1) 8 (2.3) 0.0621
Cardiovascular risk factors, n (%)
Hypercholesterolaemia 234 (84.8) 61 (17.5) <0.0001
Smoker (current/former) 186 (67.4) 198 (56.9) 0.0074
Hypertension 183 (66.3) 157 (45.1) <0.0001
Obesity† 125 (45.3) 140 (40.2) 0.2041
Diabetes 75 (27.2) 59 (17.0) 0.0020
*Statin users with missing values: DLco, n=1; 6MWD, n=4; UCSD-SOBQ, n=4. Statin
non-users with missing values: DLco, n=1; 6MWD, n=5; UCSD-SOBQ, n=3.
†Defined as a body mass index >30 kg/m2.
6MWD, 6-minute walk distance; DLco, carbon monoxide diffusing capacity;
UCSD-SOBQ, The University of California in San Diego Shortness of Breath Questionnaire.
Table 2 Unadjusted 1-year risks of study outcomes for baseline statin users and non-users*†
Outcome
Crude analysis, n (%)
Bivariate frailty model
(statin users vs non-users)
Statin users (N=276)
Statin non-users
(N=348) p Value HR 95% CI p Value
Disease-progression composite outcome‡ 103 (37.3) 152 (43.7) 0.0737 0.79 0.61 to 1.02 0.0686
First disease-progression outcome to occur§
All-cause mortality 13 (4.7) 19 (5.5)
Absolute FVC decrease ≥10% 32 (11.6) 52 (14.9)
6MWD decrease ≥50 m 62 (22.5) 92 (26.4)
Mortality
All-cause 18 (6.5) 24 (6.9) 0.8528 0.91 0.49 to 1.68 0.7557
IPF-related 15 (5.4) 23 (6.6) 0.5423 0.71 0.33 to 1.54 0.3814
FVC change
Absolute decrease ≥10% 43 (15.6) 70 (20.1) 0.1440 0.67 0.46 to 0.99 0.0417
Relative decrease ≥10% 77 (27.9) 108 (31.0) 0.3943 0.77 0.57 to 1.03 0.0814
Absolute decrease ≥5% 109 (39.5) 147 (42.2) 0.4881 0.81 0.63 to 1.04 0.0958
Relative decrease ≥5% 134 (48.6) 191 (54.9) 0.1157 0.76 0.61 to 0.95 0.0174
Death or absolute FVC decrease ≥10% 57 (9.1) 90 (14.4) 0.1277 0.71 0.51 to 0.99 0.0437
Death or 6MWD decrease ≥50 m 99 (15.9) 142 (22.8) 0.2086 0.85 0.66 to 1.10 0.2157
6MWD decrease ≥50 m 69 (25.0) 97 (27.9) 0.4918 0.85 0.62 to 1.16 0.3046
Hospitalisation
All-cause 47 (17.0) 72 (20.7) 0.2477 0.78 0.54 to 1.13 0.1818
Respiratory-related¶ 30 (10.9) 59 (17.0) 0.0309 0.64 0.41 to 1.00 0.0496
*Only confirmed cases included, defined as those for whom follow-up assessment was repeated ≥6 weeks following initial assessment and criteria for outcome were met.
†Patients with missing baseline data were excluded from relevant analyses.
‡Only first event considered in analyses.
§Number of patients who experienced each outcome as their first disease-progression event.
¶Hospitalisation in which the primary reason for admission was determined to be respiratory-related by a blinded clinical investigator.
6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.
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Previous studies undertaken to evaluate the potential impact
of statins on outcomes in patients with IPF have provided con-
ﬂicting results. A small, retrospective analysis of data from 35
patients with IPF did not show an association between statin
therapy and mortality.21 However, more than half of the
patients in this study received immunosuppressive therapy
which has recently been associated with increased mortality in
the PANTHER trial25 and which may, therefore, have con-
founded the results. In contrast, a more recent analysis of data
from the national Danish Patients Registry found that statin use
was associated with reduced mortality among 783 patients with
IPF. However, the International Classiﬁcation of Diseases, 10th
revision coding was used in this analysis, and may have intro-
duced bias due to poor deﬁnition of baseline lung function and
other potential risk factors for adverse outcomes.22
Our analyses did not identify a beneﬁcial interaction between
statin use and current/former smoking status for any outcome
contrary to previous observations reported by Alexeeff et al.
Alexeeff et al15 reported a statistically signiﬁcant (p<0.001)
three-way interaction between time since ﬁrst study visit, statin
use and smoking status in elderly men enrolled in a longitudinal
observational study. Their results suggested that statins might act
by attenuating the negative effects of smoking on the normative
decline in lung function associated with ageing. However, lung
function decline in patients with IPF differs to that associated
with normal ageing,8 26 27 thus complicating valid comparison
between the two populations.
The pathophysiology of IPF is very complex and the mechan-
ism by which statins may affect cellular and/or molecular path-
ways to reduce disease progression remains to be explained.
Repetitive microscopic injury to alveolar epithelial cells type II
(AECII) is thought to be an important component of the patho-
genesis of IPF. AECII death and perturbation of normal epithe-
lial homoeostasis may result in uncontrolled repair mechanisms,
resulting in ﬁbroblast proliferation and activation and, ultim-
ately, lung ﬁbrosis.28 29 Multiple pathways are involved both in
AECII death and in lung ﬁbrosis, and the relative contribution
of these pathways in the development of IPF is currently an
important knowledge gap. In vitro studies have long suggested a
modulatory effect of statins on pathways of ﬁbrosis in
humans.30 31 In experiments using a human renal ﬁbroblast cell
line (TK173), exposure to statins resulted in a reversible and
time-dependent change in cell morphology, including the actin
skeleton, with concomitant changes in the basal expression of
the proﬁbrotic protein connective tissue growth factor.30 This
ﬁnding was reproduced in an in vitro study that found a reduc-
tion in the expression of the proﬁbrotic connective tissue
growth factor in lung ﬁbroblasts treated with statins.32 Perhaps
more indirectly, statins have been shown to reduce the expres-
sion of the glycoprotein thrombospondin-1 by human vascular
smooth muscle cells;31 thrombospondin-1 is a known activator
of transforming growth factor-β (TGF-β), a key proﬁbrotic
protein implicated in ﬁbrogenesis.33
Pathophysiological processes other than those related directly
to ﬁbrosis may also underpin a beneﬁcial effect of statins
in patients with IPF. Statins are known to exert an
anti-inﬂammatory effect and it is possible that this action may
explain the apparent protective effect of these agents in patients
with IPF. In a rat model, statins appeared to be protective
against smoking-induced lung damage through anti-
inﬂammatory effects in the lung itself, particularly inhibition of
Figure 1 Adjusted 1-year risk of disease progression*: statin users
versus non-users. *≥10% decrease in % predicted FVC, ≥50 m decline
in 6MWD or death. 6MWD, 6-minute walk distance.
Table 3 Multivariate analyses: baseline statin users versus
non-users*
Outcome
Multivariate analyses (statin
users vs non-users)
HR 95% CI p Value
Disease progression† 0.75 0.52 to 1.07 0.1135
Mortality
All-cause 0.54 0.24 to 1.21 0.1369
IPF-related 0.36 0.14 to 0.95 0.0393
FVC
Absolute decrease ≥10% 0.81 0.47 to 1.40 0.4533
Relative decrease ≥10% 0.90 0.59 to 1.38 0.6262
Absolute decrease ≥5% 0.97 0.68 to 1.40 0.8805
Relative decrease ≥5% 0.91 0.66 to 1.25 0.5548
Death or absolute FVC decrease ≥10% 0.71 0.48 to 1.07 0.1032
Death or 6MWD decrease ≥50 m 0.69 0.48 to 0.99 0.0465
Hospitalisation
All-cause 0.58 0.35 to 0.94 0.0289
Respiratory-related‡ 0.44 0.25 to 0.80 0.0063
*Patients with missing baseline data were excluded from relevant analyses.
†Defined as ≥10% decrease in per cent predicted FVC, ≥50 m decline in 6MWD or
death.
‡Hospitalisation in which the primary reason for admission was determined to be
respiratory-related by a blinded clinical investigator.
6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.
Figure 2 Adjusted 1-year risk of ≥10% absolute FVC decline or
death: statin users versus non-users.
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inﬂammatory cell inﬁltration.34 Consistent with this latter obser-
vation, statin use was associated with reduced levels of neutro-
phils and lymphocytes in the bronchoalveolar lavage ﬂuid of
patients after lung transplantation with a variety of underlying
diagnoses including emphysema, cystic ﬁbrosis and IPF. The
6-year survival of patients with lung transplant who received
statins was also signiﬁcantly greater than that of patients who
did not receive statins (91% vs 54%; p<0.01).35 Furthermore,
statins have been shown to suppress the production of TGF-β
and the inﬂammatory chemokine, interleukin (IL) 8, in human
lung tissue.36–38 However, this is in contrast to an in vitro study
which found that statins increased mitogen-activated peripheral
blood monocyte secretion of IL-18 and IL-1β,39 two cytokines
that have been implicated in bleomycin-induced lung injury.40
Our analysis was the ﬁrst evaluation of statin use in a large,
well deﬁned cohort of patients with IPF with regular follow-up.
In contrast to earlier evidence which had suggested a link
between statin use and the development of interstitial lung
abnormalities17 18 our results add weight to the hypothesis that
statins may exert a beneﬁcial effect in patients with IPF.
However, the conclusions that can be drawn are limited by the
post hoc nature of the analysis. Statin therapy may address an
increased risk of all-cause death or hospitalisation as a result of
comorbid conditions. Yet a comparison of the baseline
characteristics of the patients in the two groups suggested that
those receiving statins had higher CV risk than those not receiv-
ing statins, as might be expected given the CV-related indica-
tions for statin therapy. Additionally, our analyses have
suggested a potentially more speciﬁc effect of statins on
IPF-related mortality and respiratory-related hospitalisations,
which might not be anticipated if the impact of statins was
related only to CV comorbidities.
Furthermore, our results are limited to patients with IPF who
are not treated with antiﬁbrotics. Future studies of statins in IPF
are likely to include patients receiving antiﬁbrotics, therefore a
post hoc analysis designed to investigate the effect of pirfeni-
done and statins in combination is planned, using data from the
pirfenidone arms of the ASCEND and CAPACITY studies.
CONCLUSIONS
In conclusion, the results presented here provide support for the
hypothesis that statins may be beneﬁcial in patients with IPF.
Future studies should include prospective analyses of statin use
in IPF and their potential use in combination with antiﬁbrotic
therapies.
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